Related by context. All words. (Click for frequent words.) 75 alvespimycin 74 HGS ETR1 74 PXD# 73 ganetespib 72 protein kinase inhibitor 72 oral prodrug 71 CRLX# 71 ENMD # 71 huC# DM4 71 PRT# 71 entinostat 71 PEG SN# 71 candidate CRLX# 71 elotuzumab 70 Xanafide 70 HGS ETR2 70 Sym# 70 OXi# 70 evaluating tivozanib 70 XL# XL# XL# XL# 70 XL# XL# 70 CD# CEA 70 CCX# 70 MEK inhibitors 70 CCR9 antagonist 70 Pharmos proprietary 70 CR# vcMMAE 70 INCB# [001] 70 neratinib 69 JAK inhibitor 69 OMP #M# 69 HGS# 69 JAK2 inhibitor 69 preclinically 69 YONDELIS 69 R#/MEM # 69 HuLuc# 69 orally dosed 69 Carfilzomib 69 enzastaurin 69 dacetuzumab 69 Pimavanserin 69 proteasome inhibitor 69 mertansine 69 cMET 69 investigational humanized monoclonal antibody 69 metaglidasen 69 Exelixis compounds 69 non nucleoside HCV 69 Azedra 69 selective androgen receptor modulator 68 Aurora kinase inhibitor 68 IMA# 68 trastuzumab DM1 T DM1 68 sodium thiosulfate STS 68 CYT# potent vascular disrupting 68 talactoferrin 68 Phase Ib study 68 telomerase therapeutic 68 MEK inhibitor 68 Hsp# inhibition 68 PSN# [002] 68 novel peptide 68 including eniluracil ADH 68 HCV protease inhibitor 68 SAR# [004] 68 Azixa 68 urocortin 2 68 ISIS # 68 BAY #-# 68 MCSP respectively 68 Phase Ib II 68 HGS ETR1 mapatumumab 68 AEG# 68 phase IIa clinical 68 pan HDAC inhibitor 68 MKC# MT 68 FOLOTYN ® 68 ALN PCS 68 PDE4 inhibitor 68 OncoVEX GM CSF 68 tezampanel 68 HuMax EGFr 68 PI3K/Akt pathway inhibitor 68 adipiplon 68 obatoclax 67 preclinical efficacy 67 XmAb# 67 investigational monoclonal antibody 67 velafermin 67 XL# anticancer compounds 67 erlotinib Tarceva ® 67 Elotuzumab 67 #D#C# 67 Symadex 67 pertuzumab 67 TRAIL receptor antibodies 67 CORT # 67 HCV protease inhibitors 67 KRN# 67 Guanilib 67 TLK# 67 PRTX 67 atacicept 67 Tarvacin TM 67 forodesine 67 Panzem R NCD 67 liposomal formulation 67 novel VDA molecule 67 tanespimycin 67 phase IIb clinical 67 radezolid 67 LY# [003] 67 TKB# 67 NEUGENE 67 receptor tyrosine kinase inhibitor 67 HCD# [002] 67 squalamine 67 JAK1 67 Tesetaxel 67 ALN VSP 66 Seliciclib 66 Virulizin ® 66 Traficet EN 66 Cloretazine ® 66 Personalized Immunotherapy 66 tubulin inhibitor 66 Bicifadine 66 HCV protease 66 Panzem 66 Romidepsin 66 cannabinor 66 oral picoplatin 66 hematological cancers 66 XL# XL# XL# 66 MEK Inhibitor 66 trastuzumab emtansine T DM1 66 AAG geldanamycin analog 66 PLK1 SNALP 66 lintuzumab SGN 66 MET amplification 66 Allovectin 7 R 66 CBLC# 66 Solazed TM 66 orally bioavailable 66 telomerase inhibitor drug 66 eprotirome 66 HQK 66 Tyrima 66 CTAP# Capsules 66 glucokinase activator 66 polymerase inhibitors 66 PS# [001] 66 vidofludimus 66 IMC #B 66 Phase Ib clinical 66 IAP inhibitors 66 AEGR 66 AP# [003] 66 TRO# 66 ocular formulation 66 delafloxacin 66 therapeutic monoclonal antibody 66 IAP inhibitor 66 Aplidin R 66 JAK2 inhibitors 66 phase IIb trial 66 kinase inhibitor 66 TPI ASM8 66 GRN# 66 axitinib 66 angiogenesis inhibitor 66 Perifosine 66 anticancer compound 66 GRN#L 66 pomalidomide 66 BAL# [001] 66 NOX E# 66 PSMA ADC 66 JAK inhibitors 66 LymphoStat B TM 66 Talabostat 66 Tezampanel 66 investigational pan BCR 66 MGCD# [001] 66 MT# MEDI 66 Archexin 66 CEQ# 66 Alocrest 66 anti amnesic 66 deforolimus 66 XmAb 66 Aganocide ® 66 DXL# 66 TMC# [002] 65 voreloxin 65 PDX pralatrexate 65 Zolinza 65 PCK# 65 epothilones 65 histone deacetylase HDAC inhibitor 65 synthetic cannabinoid library 65 TELINTRA 65 vascular disrupting agent 65 phase IIb 65 Golimumab 65 non nucleoside inhibitor 65 ularitide 65 rxRNA 65 PHX# 65 APOPTONE 65 TOCOSOL Paclitaxel 65 Blinatumomab 65 Thiarabine 65 ospemifene 65 generation nucleoside analog 65 Phase 2a trial 65 Atiprimod 65 ImmunoVEX HSV2 65 reslizumab 65 phase IIa 65 Aurexis 65 Ceflatonin R 65 rALLy clinical trial 65 Nanobody ® 65 Aflibercept 65 HCV polymerase inhibitors 65 Vilazodone 65 initiate Phase 1b 65 virus HCV protease inhibitor 65 favorable pharmacokinetic profile 65 novel anticancer 65 Thiovir 65 MAXY alpha 65 vascular disrupting agents 65 vivo efficacy 65 Pazopanib 65 trodusquemine 65 Cloretazine 65 Indibulin 65 TG# [003] 65 Phase #b/#a clinical 65 Ceflatonin 65 BRAF inhibitor 65 zanolimumab 65 EGFR HER2 65 investigational protease inhibitor 65 Aurora kinase 65 Immunotherapeutic 65 Azedra TM 65 multi kinase inhibitor 65 Omacetaxine 65 Rigel R# 65 Insegia 65 systemically administered 65 docetaxel Taxotere R 65 Pertuzumab 65 oncolytic virus therapies 65 Dapagliflozin 65 targeting CD# 65 multicenter Phase II 65 orally administered inhibitor 65 Panzem R 65 Proellex TM 65 Panzem NCD 65 BHT DNA 65 NGX# 65 leading oral taxane 65 alpha folate receptor 65 HuMax CD# 65 small molecule defensin 65 GALNS 65 AKT inhibitor 65 refractory gout 65 OMNARIS HFA 65 ATL# [001] 65 lintuzumab 65 XmAb ® 65 Vitaxin 65 Cannabinor 65 Phase 1b trial 65 Multimeric 65 TOLAMBA 65 THR beta agonist 65 MAGE A3 ASCI 65 bevacizumab Avastin ® 65 PEG Interferon lambda 65 tiapamil 65 HER2 positive metastatic breast 65 oral ridaforolimus 65 investigational compounds 65 mapatumumab 65 Hsp# inhibitor 65 selective kinase inhibitor 65 unique alkylating agent 65 ganaxolone 64 docetaxel Taxotere ® 64 Quinamed 64 SinuNase ™ 64 cancer immunotherapies 64 davunetide intranasal AL 64 GVAX ® 64 Azedra ™ 64 CINOD 64 TransVax ™ 64 sodium glucose cotransporter 64 Exherin TM 64 trastuzumab Herceptin 64 BiTE antibody 64 Zoraxel 64 Epothilones 64 Hedgehog Pathway Inhibitor 64 Phase IIB 64 BNC# 64 ongoing Phase 1b 64 HSP# inhibitor 64 sapacitabine 64 apricitabine ATC 64 Aplidin 64 Oral NKTR 64 Aganocide 64 CA4P 64 TransVax TM 64 trastuzumab Herceptin R 64 dextofisopam 64 HepeX B TM 64 Aganocide R 64 huN# DM1 64 Phase IIa trials 64 MT#/MEDI-# 64 highly selective inhibitor 64 DermaVir Patch 64 Cloretazine R VNP#M 64 PGL# 64 Kinase Inhibitor 64 Phase 1b clinical trials 64 systemic RNAi therapeutic 64 Protexia ® 64 Bortezomib 64 Tasimelteon 64 regorafenib 64 galiximab 64 Nanobody 64 mGluR5 NAM 64 Cetrorelix 64 CYC# 64 ponatinib 64 PDE# inhibitors 64 sorafenib tablets 64 generation Hsp# inhibitor 64 incyclinide 64 Pharmos pipeline 64 IL# PE#QQR 64 oral proteasome inhibitor 64 Bavituximab 64 Daclizumab 64 radiation sensitizer 64 AVN# [001] 64 GRNVAC1 64 Trofex 64 nonclinical studies 64 HuMax CD4 64 Allovectin 7 ® 64 dasatinib Sprycel ® 64 FGFR 64 DU #b 64 R roscovitine 64 sunitinib malate 64 Phase #/#a trial 64 MKC# MKC# PP 64 multitargeted 64 Ophena TM 64 Preclinical studies suggest 64 ZK EPO 64 Presents Preclinical Data 64 BRIM3 64 Glufosfamide 64 ThermoDox ® clinical 64 NVA# 64 paclitaxel Taxol ® 64 Hsp# inhibitors 64 HCV polymerase inhibitor 64 cilengitide 64 bafetinib 64 Myocet 64 IMC A# 64 proteasome inhibitors 64 CDP# 64 depsipeptide 64 SAR# [002] 64 AMPK activators 64 cediranib 64 HIV integrase inhibitors 64 VEGFR2 inhibitor 64 next generation URAT1 64 NNR Therapeutics 64 Elagolix 64 selective inhibition 64 ToGA 64 Randomized Phase 64 Androxal TM 64 GW# [003] 64 antiangiogenic activity 64 GLYX 64 MORAb 64 PRX # 64 eniluracil 64 TLR9 agonist 64 ELACYT 64 class mGluR5 inhibitor 64 TACI Ig 64 hematological tumors 64 otelixizumab 64 Dasatinib 64 solithromycin 64 ThermoDox R 64 riociguat 64 mitogen activated ERK kinase 64 Serdaxin 64 drug pipeline TAFA# 64 AVE# 64 Onconase 64 DAVANAT 64 Shigamabs ® 64 Trofex TM 64 relapsed multiple myeloma 64 Varespladib 64 telaprevir VX 64 Sapacitabine 64 Zybrestat 64 farletuzumab 63 talabostat 63 BioVant 63 defensin mimetic antibiotic 63 Alinia 63 Sphingomab 63 hematological malignancies 63 MyVax R 63 bardoxolone 63 A3 adenosine receptor 63 imetelstat 63 teriflunomide 63 trastuzumab DM1 63 ADP receptor antagonist 63 myelofibrosis polycythemia vera 63 Imprime PGG 63 Aurora kinase inhibitors 63 #th Annual Interscience 63 XOMA 3AB 63 nucleoside analog 63 MEK inhibitor RDEA# 63 mGluR5 negative 63 BCX# 63 ARRY # 63 ulimorelin 63 oral nucleoside analogue 63 ALN TTR 63 Dacogen injection 63 NXL# 63 PrevOnco 63 Plicera 63 TELCYTA 63 teduglutide 63 EndoTAG TM -1 63 Fx #A 63 Phenoptin 63 ASONEP 63 novel histone deacetylase 63 Zemiva TM 63 imatinib Gleevec ® 63 oral FTY# 63 Locteron ® 63 catheter occlusion 63 2 inhibitor CYT# 63 Civacir 63 Vaxfectin TM 63 acyclovir Lauriad R 63 Cloretazine R 63 mGluR2 NAM 63 HCV polymerase 63 epigenetic therapies 63 GLPG# 63 Debio 63 volociximab 63 nucleotide analog 63 antagomirs 63 small molecule tyrosine 63 L BLP# 63 EOquin TM 63 ALS #-# 63 IMiDs ® 63 Epratuzumab 63 isoform selective 63 delta isoform 63 Mipomersen 63 Triapine 63 Pivotal Phase III 63 ATL/TV# 63 HDAC Inhibitor 63 oral antiviral 63 bortezomib Velcade 63 Enzastaurin 63 ORAL Sync 63 Voreloxin 63 R#/MEM 63 Hsp# Inhibitor 63 BRIM2 63 targeted radiotherapeutic 63 SARMs 63 Onalta 63 valopicitabine 63 Adnectin 63 immunomodulatory 63 YONDELIS R 63 PROSTVAC TM 63 phase Ib 63 humanized antibodies 63 sunitinib Sutent ® 63 ON #.Na 63 Phase III Pivotal 63 NEUGENE antisense 63 gefitinib Iressa 63 ceftazidime 63 PNP inhibitor 63 Reports Preclinical Data 63 Factor VIIa 63 midstage clinical 63 INGN 63 humanized monoclonal antibody 63 NKTR 63 INT# [002] 63 custirsen 63 generation URAT1 inhibitor 63 FOLFOX6 chemotherapy regimen 63 CoFactor 63 Phase 2a 63 Vascugel 63 MGd 63 GVAX R 63 selective orally bioavailable 63 Phase Ib clinical trials 63 Bezielle 63 Marqibo TM 63 Phase 2b Clinical Trial 63 thalidomide Thalomid 63 2 methoxyestradiol 63 polymerase inhibitor 63 dasatinib Sprycel 63 motesanib 63 Valortim 63 Zalypsis 63 #I TM# 63 CRx 63 PKC# 63 KNS # 63 HCV NS5B polymerase 63 CD# antibody [001] 63 ONCONASE R 63 Novolimus 63 SCH # 63 antibody MAb 63 posaconazole 63 imetelstat GRN#L 63 SLx 63 LEP ETU 63 anti leukemic 63 secretory phospholipase A2 sPLA2 63 Genasense ® oblimersen 63 OncoVex 63 teplizumab 63 Completes Patient Enrollment 63 oncology therapeutics 63 PORxin TM platforms 63 DPX Survivac 63 Naproxcinod 63 anticoagulant reversing agent 63 Squalamine 63 INCB# [002] 63 TKM ApoB 63 tezampanel NGX# 63 integrase inhibitor 63 AeroLEF TM 63 TAFA# 63 phase III isavuconazole 63 SUTENT ® 63 APTIVUS 63 Presents Preclinical 63 DEB# 63 Capesaris 63 R sorafenib tablets 63 viral kinetics 63 Initiates Enrollment 63 ZYBRESTAT fosbretabulin 63 GAMMAGARD 63 JVRS 63 Clonicel 63 CD# monoclonal antibody 63 Ridaforolimus 63 sarcoma melanoma 63 LUX Lung 63 fosbretabulin 63 small molecule inhibitors 63 NEUVENGE 63 ProSavin 63 IRX 2 63 HCV SPRINT 63 OMP #R# 63 Annamycin 63 DOS# 63 cathepsin K inhibitor 63 BiTE antibodies 63 Lenocta TM 63 anti CD3 antibody 63 CRMD# 63 Zemiva ™ 63 Amigal 63 DDP# 63 agonistic human 63 iroxanadine 63 novel immunomodulatory 63 pegylated interferons 63 LAF# 62 MDV# 62 lenalidomide Revlimid R 62 Tanespimycin 62 belinostat 62 vinca alkaloid 62 investigational HCV polymerase 62 drug conjugate 62 VQD 62 neuroprotective properties 62 preclinical compounds 62 MAP# 62 adecatumumab 62 Cloretazine VNP#M 62 Zenvia ™ 62 TriRima 62 PEG PAL 62 Phase 1a clinical 62 LymphoStat B 62 cetuximab Erbitux R 62 Begins Dosing 62 GMX# 62 novel topoisomerase 62 GSK # 62 VEGF inhibitors 62 vemurafenib 62 CB2 selective receptor agonist 62 subcutaneous PRO 62 Cetuximab Erbitux 62 ELND-#/AZD-# 62 Lisofylline LSF 62 pradefovir 62 ASA# 62 Anidulafungin 62 ALN TTR# 62 midstage trials 62 anticancer activity 62 Akt inhibitor 62 GAP #B# 62 Nanobody R 62 HDAC inhibition 62 ZOLINZA 62 panitumumab Vectibix 62 SNT MC# 62 bendamustine 62 Solulin 62 IDX# 62 Triolex 62 sodium Injection 62 anti EGFR antibody 62 Hepatocellular Carcinoma HCC 62 TREANDA 62 Intravenous Human 62 antitumor activity 62 HuMax TAC 62 Nexavar ® 62 dimebon latrepirdine 62 lixivaptan 62 Nasdaq IDRA today 62 OvaRex R 62 HspE7 62 MAXY G# 62 MGCD# [002] 62 targeted kinase inhibitor 62 XP# XP# 62 ® bortezomib 62 Targretin 62 fostamatinib 62 elvucitabine 62 BRAF kinase 62 targeted antifolate 62 Phase #/#a 62 SERMs 62 MLN# 62 rNAPc2 62 elesclomol 62 DURECT proprietary 62 celgosivir 62 ALN HTT 62 Targeted Chemotherapy 62 Pathway Inhibitor 62 TLR antagonists 62 CD4 monoclonal antibody 62 panobinostat 62 histone deacetylase inhibitor 62 peripherally acting 62 pralatrexate 62 bicifadine 62 Serdaxin ® 62 lucinactant 62 Denufosol 62 Aliskiren 62 BiTE R 62 randomized Phase 2b 62 myeloproliferative disorders 62 Entereg R 62 AEZS 62 samalizumab 62 demonstrated antitumor activity 62 Cyclooxygenase Inhibiting Nitric Oxide 62 ABL inhibitor 62 REG1 Anticoagulation System 62 nucleoside analogues 62 NovaBay Aganocide compounds 62 Tarceva erlotinib 62 Maribavir 62 Ophena 62 Dalbavancin 62 TRACON Pharmaceuticals 62 eosinophilic asthma 62 LHRH receptor positive 62 nucleotide analogue 62 targeted protein kinase 62 EXPLORE Xa 62 vaccine GRNVAC1 62 ocrelizumab 62 XL# SAR# 62 eltrombopag 62 vicriviroc 62 Intravenous CP 62 oral gallium 62 ProLindac TM 62 Nexavar sorafenib 62 lexidronam injection 62 IMiDs R 62 CCR5 antagonist 62 Nanobodies 62 maximally tolerated dose 62 peptibody 62 mTOR inhibitors 62 indibulin 62 Prodarsan R 62 TRV# [001] 62 products MKC# PP 62 NABTT 62 Phase 2a clinical 62 immunological diseases 62 Inc. Nasdaq IMGN 62 placebo controlled Phase III 62 NEUMUNE 62 AACR NCI EORTC 62 MYCAMINE 62 Solorel TM 62 candidate AQ4N 62 paclitaxel Taxol 62 hypoxia selective 62 humanized anti 62 MOZOBIL 62 immune stimulatory 62 Allovectin 7 r 62 generation NNRTI 62 CCR9 62 Phase Ib 62 S/GSK# 62 RDEA# 62 SUCCEED trial 62 Hedgehog antagonist 62 Imetelstat 62 Antitumor Activity 62 tolevamer 62 IMiD 62 solid tumors ZYBRESTAT 62 tramiprosate Alzhemed TM 62 ALN HPN 62 LentiVector technology 62 pharmacokinetic PK study 62 metastatic castration resistant 62 CIMZIA ™ 62 tolerability profiles 62 MVA BN R 62 anticancer therapy 62 subcutaneous formulation 62 immunosuppressive compound 62 Neulasta ® 62 xenograft models 62 Meets Primary Endpoint 62 LymphoStat B belimumab 62 PI3K inhibitor 62 novel DACH platinum 62 Valortim R 62 Telik logo TELINTRA 62 AQ4N 62 recurrent metastatic ovarian cancer 62 immune modulating 62 nilotinib Tasigna ® 62 docetaxel Taxotere 62 TLR8 62 Phase 2b clinical 62 Enzyme Replacement Therapy 62 Allovectin 7 62 REP# 62 PLX# 62 Litx 62 SinuNase TM 62 Cerashield 62 Curaxin CBLC# 62 NP2 Enkephalin 62 olaparib 62 EndoTAG TM 62 lead Aganocide compound 62 GSK# [002] 62 oral taxane 62 Factor Receptor 62 forodesine hydrochloride 62 anticancer agents 62 partial agonist 62 SYN# 62 apoptosis inducer 62 milatuzumab 62 Clinical Trial Results 62 CXB# 62 epothilone 62 Vicriviroc 62 LHRH antagonists 62 P#X# antagonist 62 Stedivaze 62 daptomycin 62 OHR/AVR# 62 iSONEP 62 Phase IIb trials 62 Initiates Phase II 62 Xcytrin R 62 Cethromycin 62 alkylating agent 62 Triapine R 62 Smac mimetics 62 ENMD 62 triphendiol 62 Vandetanib 62 romazarit 62 RhuDex ® 62 BZL# 62 L Annamycin 62 Telatinib 62 vilazodone 62 Genz # 62 potent antiviral 62 Nanobodies ® 62 SIRT1 activators 62 novel nucleoside analog 62 clinical trials SGN 62 LE SN# 62 lesinurad 62 small molecule thrombopoietin 62 antiangiogenic agents 62 iniparib 62 Lu AA# 62 protein kinase inhibitors 62 severe hypercholesterolemia 62 LibiGel ® 62 preclinical studies 62 ApoB SNALP 61 ZFP Therapeutics 61 registrational trial 61 velafermin belinostat 61 PSN# [001] 61 Apoptone 61 elacytarabine 61 Altastaph 61 seliciclib 61 selective androgen receptor modulators 61 vivo preclinical 61 ICA # 61 ProLindac 61 prostone 61 Phase 1b 61 Vidaza ® 61 Ocrelizumab 61 TRIOLEX 61 Onalta ™ 61 GetGoal Phase III 61 hypoxia activated prodrug 61 UPLYSO 61 lomitapide 61 Phase IIb clinical trials 61 Tesmilifene 61 compound INCB# 61 romidepsin 61 Tarceva TM 61 potent anti angiogenic 61 EPX # 61 Prodarsan ® 61 lapatinib Tykerb 61 includes TOLAMBA TM 61 Deforolimus 61 hematologic cancers 61 recombinant biopharmaceutical 61 trabectedin 61 ZFP Therapeutic 61 PF # [001] 61 AzaSite Plus 61 Phase IIIb clinical 61 TLR7 61 Phase 2a clinical trials 61 faropenem 61 TBC# 61 PORxin TM 61 CUDC 61 Synavive 61 www.telik.com 61 Onco TCS 61 Randomized Double blind 61 varespladib 61 SRT# [003] 61 Radezolid 61 EP #R 61 Phase 2a Study 61 Anticalin R 61 Protexia R 61 Desmoteplase 61 adecatumumab MT# 61 retapamulin 61 PEGylated irinotecan 61 inhibitor RG# 61 relapsed MM 61 HuCAL antibodies 61 predictive biomarkers 61 TYZEKA 61 TG# [001] 61 lumiliximab 61 dextromethorphan quinidine 61 CORLUX CORT # 61 OvaRex ® MAb 61 chemopreventive agent 61 Lenocta 61 Granulocyte Colony Stimulating Factor 61 CK # novel 61 antithrombotic 61 placebo controlled Phase 61 IMiDs 61 ruxolitinib 61 candidate deforolimus 61 HepeX B 61 rALLy trial 61 Antiangiogenic 61 pharmacokinetic interactions 61 cyclophilin inhibitor 61 Bendavia 61 ARIKACE ™ 61 ESBA# 61 Campath ® 61 nab paclitaxel 61 Imprime PGG ® 61 Adenosine Therapeutics 61 PDE# 61 Romiplostim 61 dacetuzumab SGN 61 aleglitazar 61 ongoing Phase IIIb 61 NV1FGF 61 PEGylated interferon beta 1a 61 nicotinic alpha 7 61 PI3K/mTOR 61 Teplizumab 61 retaspimycin 61 monoclonal antibody IgG1 Mab 61 Preclinical Data 61 Opexa 61 oral JAK1 61 5 HT6 61 thiazolides 61 DGAT1 inhibitors 61 Hedgehog pathway inhibitor 61 Novel Oral 61 LBH# 61 LEUKINE 61 evaluating satraplatin 61 TRIOLEX ™ 61 NNRTIs 61 Nektar proprietary 61 GLP toxicology studies 61 SPRYCEL ® 61 Intarcia 61 IgG1 monoclonal antibody 61 Safinamide 61 preclinical 61 PARP inhibitor 61 Phase IIa clinical trials